Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 4/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20108162 | 0.81 | KMT2A (0.48) | KMT2AMEN1CYP1A2PLK1PLK3 | |
| SCHEMBL577918 | 0.80 | PLK1 (0.46) | ALDH1A1SCN1ASCN5ASCN8APLK1 | |
| SCHEMBL1373718 | 0.79 | PLK1 (0.46) | SCN1ASCN5ASCN8APLK1PLK3 | |
| SCHEMBL2973598 | 0.79 | PLK1 (0.48) | RAB9APLK1PLK3CDK2IKBKE | |
| SCHEMBL577919 | 0.79 | PLK1 (0.46) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL4552924 | 0.79 | PLK1 (0.48) | RAB9APLK1PLK3CDK2IKBKE | |
| SCHEMBL8929156 | 0.78 | PLK1 (0.45) | PLK1PLK3CDK2IKBKEMAPT | |
| SCHEMBL20505093 | 0.77 | KMT2A (0.61) | KMT2AALDH1A1SMN1; SMN2MEN1POLB | |
| SCHEMBL2986978 | 0.76 | ALDH1A1 (0.43) | ALDH1A1POLBPLK1PLK3CDK2 | |
| Hydrochloric Acid SCHEMBL8194482 | 0.74 | KMT2A (0.57) | KMT2AALDH1A1SMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759389-B1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759389-B1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759389-B1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-24 | — | — | US | disclosed |
| US-8399478-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399478-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399478-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-2474546-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | Vertex Pharmaceuticals Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474546-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | Vertex Pharmaceuticals Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1989205-B1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7915305-B2 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915305-B2 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1989205-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmceuticals Incorporated (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| WO-2007087283-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087283-A2 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | KMT2A 784/4885ALDH1A1 4111/4885SMN1; SMN2 2508/4885 |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | KMT2A 1819/4885ALDH1A1 1939/4885SMN1; SMN2 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.